Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | L3MBTL3 | Q96JM7 | 6/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.49 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.46 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30249029 | 0.98 | MAPK1 (0.52) | MAPK1CHRM1L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL12967015 | 0.85 | MAPK1 (0.70) | MAPK1CHRM1L3MBTL1TP53TDP1 | |
| SCHEMBL25905001 | 0.83 | MAPK1 (0.53) | MAPK1CHRM1L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL8133852 | 0.82 | MAPK1 (0.52) | MAPK1CHRM1L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL17803881 | 0.82 | ALDH1A1 (0.47) | CHRM1L3MBTL1MEN1KMT2A | |
| SCHEMBL2911537 | 0.82 | ALDH1A1 (0.47) | CHRM1L3MBTL1MEN1KMT2A | |
| SCHEMBL25894390 | 0.81 | MAPK1 (0.58) | MAPK1CHRM1L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL2911286 | 0.80 | ALDH1A1 (0.48) | L3MBTL1 | |
| SCHEMBL22852237 | 0.80 | MAPK1 (0.53) | MAPK1CHRM1L3MBTL3L3MBTL1MBTD1 | |
| SCHEMBL22852060 | 0.80 | MAPK1 (0.53) | MAPK1CHRM1L3MBTL3L3MBTL1MBTD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114341128-B | Bifunctional protein degradation targeting chimeric compound, preparation method and medical application thereof | 恩瑞生物医药科技（上海）有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20230151024-A1 | STING AGONISTIC COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230151024-A1 | STING AGONISTIC COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230151024-A1 | STING AGONISTIC COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230141284-A1 | CANCER THERAPEUTIC METHOD | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20230141284-A1 | CANCER THERAPEUTIC METHOD | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-05-11 | — | — | US | disclosed |
| WO-2023023347-A1 | PRODRUGS AND DERIVATIVES OF PSILOCIN AND USES THEREOF | TERRAN BIOSCIENCES INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| EP-4134134-A1 | STING AGONISTIC COMPOUND | ONO Pharmaceutical Co., Ltd. (JP) | 2023-02-15 | — | — | EP | disclosed |
| EP-4134098-A1 | METHOD OF CANCER THERAPY | ONO Pharmaceutical Co., Ltd. (JP) | 2023-02-15 | — | — | EP | disclosed |
| EP-4134134-A1 | STING AGONISTIC COMPOUND | ONO Pharmaceutical Co., Ltd. (JP) | 2023-02-15 | — | — | EP | disclosed |
| CN-114341128-A | Bifunctional protein degradation targeting chimera compound and preparation method and medical application thereof | 恩瑞生物医药科技（上海）有限公司 | 2022-04-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141284-A1 | CANCER THERAPEUTIC METHOD | STING1, CGAS, IFNAR1 | MAPK1 2393/4885CHRM1 2613/4885L3MBTL3 4699/4885 |
| US-20230151024-A1 | STING AGONISTIC COMPOUND | STING1, CGAS, TLR1 | MAPK1 1542/4885CHRM1 207/4885L3MBTL3 3687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.